Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
6/2/2026, 12:00:00 AM
European Commission approved AQUIPTA (atogepant) for acute migraine treatment on 2026-06-02. Low importance as label expansions typically result in moderate price movement.
Korean Translation
2026년 6월 2일, 유럽연합 집행위원회가 아큅타(아토게판트)의 편두통 급성 치료 적응증 확대를 승인함. 적응증 확대에 따른 통상적인 시장 반응을 고려하여 중요도를 낮게 평가함.
Related Recent Events
Target Corp (TGT) · Earnings Release
Target's Q2 2026 earnings release is set for August 19, 2026; low importance is estimated as the date announcement itself typically has a market impact of less than 5%, scheduled.
8/19/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
AST SpaceMobile Inc (ASTS) · Earnings Release
Q2 2026 earnings release and conference call for August 10, 2026, which is expected to have a medium impact by providing key financial updates, scheduled.
8/10/2026, 12:00:00 AM
Chevron Corp (CVX) · Earnings Release
Q2 2026 earnings release is scheduled for August 7, 2026; analysts forecast a significant increase in earnings due to higher oil prices and full integration of Hess assets. Market impact is estimated at Medium (5%) as earnings are a primary driver of stock volatility, scheduled.
8/7/2026, 12:00:00 AM
Akamai Technologies Inc (AKAM) · Earnings Release
Q2 2026 earnings release scheduled for 2026-08-06. Analysts forecast EPS of around $1.60 forecasted. High importance estimated due to the 26% price movement in the previous earnings release scheduled.
8/6/2026, 12:00:00 AM
Consolidated Edison Inc. (ED) · Earnings Release
Q2 2026 earnings release on 2026-08-06 is scheduled. Low importance is estimated as the primary market impact occurs on the release date, scheduled.
8/6/2026, 12:00:00 AM